Viking Therapeutics, Amgen, and the Next-Generation Obesity Pipeline
While Eli Lilly consolidates its lead in the obesity therapeutics market, a second wave of companies is advancing candidates that […]
Industry
Novo Nordisk’s CagriSema Fails to Beat Tirzepatide in Head-to-Head Trial
Novo Nordisk’s next-generation weight-loss candidate CagriSema — a fixed-ratio combination of semaglutide and the amylin analog cagrilintide — failed to demonstrate superiority